Clinical Trials & Emerging Therapies in Cystic Fibrosis
Clinical trials in cystic fibrosis (CF) are focused on breakthrough therapies such as CFTR modulators, including Trikafta, which aim to correct the underlying genetic defect and improve lung function. Other promising treatments include gene therapy, mRNA-based treatments, and anti-inflammatory agents to reduce lung damage. Emerging therapies also target improving mucus clearance, preventing infections, and addressing nutritional deficiencies. Advances in precision medicine, early detection through biomarkers, and personalized care plans are enhancing the quality of life and survival rates for CF patients.